<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the management of central nervous system tumors in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the management of central nervous system tumors in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the management of central nervous system tumors in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ching Lau, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wan-Yee Teo, MBBS, FAAP, MRCPCH (UK), FRCP Edin, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David G Poplack, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies, after hematologic malignancies, and are the most common pediatric solid organ tumor  (<a class="graphic graphic_table graphicRef99680" href="/z/d/graphic/99680.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. They are the leading cause of death from childhood cancer, surpassing the mortality rate of acute lymphoblastic leukemia [<a href="#rid2">2</a>]. Although advances in surgical intervention, radiation therapy, and chemotherapy have improved the survival rates in children with CNS tumors, mortality and morbidity associated with these disorders persist, especially with malignant brain tumors.</p><p>A general overview of the management and prognosis of CNS tumors in children will be reviewed here. An overview of the clinical manifestations, diagnosis, and epidemiology of CNS tumors in children is presented separately. (See  <a class="medical medical_review" href="/z/d/html/6250.html" rel="external">"Clinical manifestations and diagnosis of central nervous system tumors in children"</a> and  <a class="medical medical_review" href="/z/d/html/6251.html" rel="external">"Epidemiology and classification of central nervous system tumors in children"</a>.)</p><p>The management and prognosis of specific CNS tumors that occur in children are discussed in greater detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Low-grade gliomas (see  <a class="medical medical_review" href="/z/d/html/5198.html" rel="external">"Treatment and prognosis of IDH-mutant astrocytomas in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignant gliomas (see  <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brainstem glioma (see  <a class="medical medical_review" href="/z/d/html/5229.html" rel="external">"Diffuse intrinsic pontine glioma"</a> and  <a class="medical medical_review" href="/z/d/html/5191.html" rel="external">"Focal brainstem glioma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optic glioma (see  <a class="medical medical_review" href="/z/d/html/5226.html" rel="external">"Optic pathway glioma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medulloblastoma (see  <a class="medical medical_review" href="/z/d/html/5219.html" rel="external">"Clinical presentation, diagnosis, and risk stratification of medulloblastoma"</a> and  <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">"Histopathology, genetics, and molecular groups of medulloblastoma"</a> and  <a class="medical medical_review" href="/z/d/html/88801.html" rel="external">"Treatment and prognosis of medulloblastoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Craniopharyngioma (see  <a class="medical medical_review" href="/z/d/html/5210.html" rel="external">"Craniopharyngioma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ependymoma (see  <a class="medical medical_review" href="/z/d/html/5224.html" rel="external">"Intracranial ependymoma and other ependymal tumors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal brainstem glioma (see  <a class="medical medical_review" href="/z/d/html/5191.html" rel="external">"Focal brainstem glioma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Germ cell tumors (see  <a class="medical medical_review" href="/z/d/html/5199.html" rel="external">"Intracranial germ cell tumors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intradural nerve sheath tumors, such as schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors (see  <a class="medical medical_review" href="/z/d/html/5196.html" rel="external">"Intradural nerve sheath tumors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningioma (see  <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spinal cord tumors (see  <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">"Spinal cord tumors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberous sclerosis (see  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other tumors, including neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid/rhabdoid tumors, ependymoblastoma, and medulloepithelioma (see  <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">"Uncommon brain tumors"</a>)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MANAGEMENT STRATEGY</span><span class="headingEndMark"> — </span>The mainstay of management in CNS tumors includes a multimodal approach of surgery, radiation therapy, and chemotherapy. The confirmation of a CNS tumor warrants a referral to a neurosurgeon for further evaluation, tissue biopsy, and gross total resection where possible. Radiation therapy and chemotherapy are used as adjunct measures based on the histology of the tumor.</p><p class="headingAnchor" id="H3"><span class="h1">SURGERY</span><span class="headingEndMark"> — </span>An open surgical procedure is the preferred approach to obtain tissue for a histologic diagnosis and bulk removal of the tumor where possible. A pediatric neurosurgeon should be involved, if possible, as they are best able to perform tumor resection with limited long-term morbidity [<a href="#rid3">3</a>]. In most cases, near-total resection can be achieved. However, complete resection is generally limited by the inability to remove the tumor with surrounding clear margins of normal tissue because of the risk of producing permanent neurologic deficits, and to remove scattered tumor cells that have infiltrated beyond the margins of the resection [<a href="#rid4">4</a>]. Adjunct therapy (ie, radiation therapy and chemotherapy) is required.</p><p>Deep-seated tumors, such as diffuse infiltrative brainstem and chiasmatic gliomas, are associated with a high risk of irreversible neurologic sequelae in an open surgical approach. In these cases, tissues for histologic diagnosis can be obtained using stereotactic biopsy techniques guided by magnetic resonance imaging (MRI) or computed tomography (CT) [<a href="#rid4">4,5</a>]. Endoscopic biopsy is another option for intraventricular or periventricular tumors [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Surgical approaches and techniques</span><span class="headingEndMark"> — </span>The major risk of extensive tumor resection is injury to the surrounding tissue, especially in functionally critical parts of the brain, which can result in long-term neurologic impairment. Advances in operative microscopy with better visualization of the interface between the tumor and the surrounding normal tissue have resulted in safer surgical resection and lower neurologic morbidity.</p><p>In cases where the tumor is in a functionally critical site and/or there is poor demarcation of the tumor from its surroundings, the following techniques have been used to minimize injury to the adjacent normal tissue:</p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative stereotactic imaging to guide the surgical approach in order to minimize manipulation of normal tissue and maximize tumor resection [<a href="#rid7">7</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraoperative MRI, including functional MRI to aid in intraoperative decision making [<a href="#rid5">5,7</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraoperative neurophysiologic monitoring of visual, auditory, and somatosensory pathways in cases that involve functionally critical zones to minimize injury to normal tissue [<a href="#rid7">7,8</a>]</p><p></p><p>Postoperative imaging, preferably by MRI, is performed within the first 24 to 72 hours to determine the extent of tumor resection. This information is useful in the planning of subsequent therapy, including the need for repeat surgery.</p><p class="headingAnchor" id="H5"><span class="h2">Preoperative and perioperative considerations</span><span class="headingEndMark"> — </span>In addition to deciding the optimal surgical approach and technique to adopt for a child with a CNS tumor, the following preoperative and perioperative complications have to be addressed:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased intracranial pressure (ICP) including obstructive hydrocephalus</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine abnormalities</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Elevated intracranial pressure</span><span class="headingEndMark"> — </span>Elevated ICP is a common finding in children with CNS tumors and can be caused by mass effect of the tumor and/or obstructive hydrocephalus. Patients who have radiographic and/or clinical signs of elevated ICP require urgent neurosurgical intervention (eg, tumor resection and/or placement of a shunt to relieve hydrocephalus, if present) to prevent serious morbidity and death.</p><p>Although tumor resection may lead to resolution of hydrocephalus, preoperative shunting is often performed to temporarily relieve the increased ICP, reducing the potential risk of herniation. Shunting is usually performed by placing an external ventricular drain  (<a class="graphic graphic_figure graphicRef56391" href="/z/d/graphic/56391.html" rel="external">figure 1</a>) just prior to craniotomy for tumor resection. Postoperatively, the shunt allows drainage of bloody cerebrospinal fluid (CSF) and debris. It is usually removed within a few days after normal CSF flow is reestablished following tumor resection. In cases with persistent obstruction of CSF flow, a long-term CSF shunting procedure may be required (eg, a ventriculoperitoneal shunt or endoscopic third ventriculostomy, in which a perforation is made to connect the third ventricle to the subarachnoid space). These procedures are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/111138.html" rel="external">"Hydrocephalus in children: Management and prognosis", section on 'CSF diversion procedures'</a>.)</p><p>Patients with elevated ICP due to CNS tumors are typically treated with glucocorticoid therapy (eg, <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>) in the perioperative period to reduce peritumor edema associated with the surgical procedure. Intravenous or oral dexamethasone (0.25 to 0.5 mg/kg administered every six hours with a maximum dose of 16 mg per day) is given preoperatively and is continued intraoperatively and during the early postoperative period. In most cases, dexamethasone can be discontinued after a few days because tumor volume is reduced following resection. However, children with tumors that are not amenable to resection (eg, brainstem lesions) may require protracted dexamethasone therapy and are at risk for its side effects. The use of dexamethasone in this setting is supported by indirect evidence in studies involving adult patients with symptomatic primary and metastatic brain tumors [<a href="#rid9">9</a>]. These data are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors", section on 'Initiation of glucocorticoids'</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>Seizures are common in patients with brain tumors, and epileptogenesis is probably multifactorial [<a href="#rid10">10</a>]. In one study, the following factors were associated with increased risk of seizure perioperatively at the time of brain tumor resection [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Supratentorial tumor location</p><p class="bulletIndent1"><span class="glyph">●</span>Young age (&lt;2 years)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyponatremia</p><p></p><p>Tumor pathology and tumor size did not appear to be associated with increased risk of seizure [<a href="#rid11">11</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of seizures</strong> – Anticonvulsant therapy is indicated for patients with CNS tumors complicated by seizures. Agents that are commonly used include <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a>, <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproic acid</a>, <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">lamotrigine</a>, <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">topiramate</a>, <a class="drug drug_pediatric" data-topicid="13330" href="/z/d/drug information/13330.html" rel="external">gabapentin</a>, and <a class="drug drug_pediatric" data-topicid="117868" href="/z/d/drug information/117868.html" rel="external">pregabalin</a>.</p><p></p><p class="bulletIndent1">Drug interactions are important to consider in selecting an antiseizure medication in patients with brain tumors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">Phenytoin</a> induces the cytochrome P450 enzymes, increasing the clearance and decreasing the effectiveness of chemotherapeutic agents that are metabolized through this system (eg, nitrosoureas, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>, <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">etoposide</a>, <a class="drug drug_pediatric" data-topicid="13005" href="/z/d/drug information/13005.html" rel="external">topotecan</a>, <a class="drug drug_pediatric" data-topicid="13238" href="/z/d/drug information/13238.html" rel="external">irinotecan</a>, <a class="drug drug_pediatric" data-topicid="12838" href="/z/d/drug information/12838.html" rel="external">thiotepa</a>, <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">doxorubicin</a>, <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">methotrexate</a>, and corticosteroids) [<a href="#rid10">10</a>]. Phenytoin levels should be monitored closely in patients treated concomitantly with <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> (particularly during tapering and after discontinuation) because dexamethasone can alter the blood concentration of phenytoin [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">Valproic acid</a> inhibits hepatic enzyme expression, reducing metabolism of some chemotherapeutic drugs, leading to increased risk of toxicity. Toxic effects of nitrosoureas, given alone or with <a class="drug drug_pediatric" data-topicid="13162" href="/z/d/drug information/13162.html" rel="external">cisplatin</a> and <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">etoposide</a>, have been reported with concomitant administration of valproic acid [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other anticonvulsants that affect P450 enzymes include <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> and <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Many chemotherapeutic agents induce coenzymes of the cytochrome P450 pathway and change the plasma concentration of concomitantly prescribed antiseizure medications.</p><p></p><p class="bulletIndent1">More information on specific drug interactions is available through the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic antiseizure medication</strong> – Based upon the available evidence, we recommend <strong>not</strong> using prophylactic anticonvulsants in patients without a history of seizures. The exception is the use of postoperative seizure prophylaxis at the discretion of the neurosurgeon. This approach is consistent with the consensus statement from the Quality Standards Subcommittee of the American Academy of Neurology [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Clinical trials in adult patients with brain tumors without history of prior seizures have demonstrated that prophylactic anticonvulsants do not reduce the frequency of seizures and are associated with increased risk of adverse events [<a href="#rid13">13</a>]. Although most studies are of adult patients with brain tumors, the results are most likely applicable to pediatric patients as well. (See  <a class="medical medical_review" href="/z/d/html/5181.html" rel="external">"Seizures in patients with primary and metastatic brain tumors", section on 'Indications for antiseizure medication therapy'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Endocrine abnormalities</span><span class="headingEndMark"> — </span>Patients with lesions located in the hypothalamus or pituitary gland may present with endocrine abnormalities, such as growth failure due to either hypothyroidism or growth hormone deficiency. One example is craniopharyngioma, which often presents with endocrine abnormalities due to its location near the optic chiasm and pituitary axis (see  <a class="medical medical_review" href="/z/d/html/5210.html" rel="external">"Craniopharyngioma"</a>). Tumor resection can exacerbate endocrine dysfunction. For example, patients whose posterior pituitary gland is injured or resected during surgery may have impaired fluid and electrolyte regulation with an initial phase of transient arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus), followed by a period of inappropriate antidiuretic hormone release, and a final persistent phase of AVP-D. (See  <a class="medical medical_review" href="/z/d/html/5210.html" rel="external">"Craniopharyngioma"</a> and  <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p></p><p>Management of the specific endocrine abnormalities may require hormonal replacement therapy.</p><p class="headingAnchor" id="H9"><span class="h1">RADIATION THERAPY</span><span class="headingEndMark"> — </span>Radiation therapy plays an integral role in the treatment of CNS tumors in children. The use of radiation therapy is dependent on the histologic diagnosis of the tumor, whether there is an effective chemotherapeutic alternative, and the age of the child. Radiation therapy is usually avoided in children &lt;3 years old because of the risk of severe neurocognitive sequelae. (See  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Neurocognitive effects'</a>.)</p><p>When radiation therapy is selected, planning the target volume (local versus craniospinal) and the dose of radiation therapy takes into consideration the tumor location, stage and subtype of the tumor, expected patterns of spread, availability of effective chemotherapy, and age of the patient.</p><p>Radiation therapy is generally delivered by conventional external beam. Other techniques include three-dimensional conformal radiation therapy (targeting the radiation to conform to the size and shape of the tumor) and stereotactic radiosurgery. The different techniques of radiation therapy administration are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer"</a> and  <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery"</a>.)</p><p>Although an effective adjunct, radiation therapy is associated with both acute and long-term complications, particularly in infants and young children whose nervous systems are still developing. The complications of cranial radiation can be categorized into three phases and are summarized as follows. A more detailed discussion of the complications of cranial radiation is provided in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/7053.html" rel="external">"Acute complications of cranial irradiation"</a> and  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Acute reactions occur during treatment and are caused by injury to the brain that results in inflammation and edema. Symptoms include headache, nausea, drowsiness, focal neurologic deficits, and fever.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early-delayed reactions occur from a few weeks to three months after radiation treatment and are thought to be due to a combination of tumor response, peritumor edema, and demyelination. Findings include transient focal neurologic deficits, somnolence syndrome (characterized by extreme sleepiness and signs of increased intracranial pressure [ICP], such as headache, nausea, vomiting, anorexia, and irritability), and asymptomatic magnetic resonance imaging (MRI) contrast enhancement, which may be difficult to distinguish from tumor progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late reactions occur &gt;90 days after radiation treatment and generally are irreversible. They are due to radiation-induced brain necrosis at or near the site of the tumor that has received the highest radiation dose, diffuse white matter injury (ie, leukoencephalopathy), secondary malignancies, and vasculopathy. General findings include impaired neurocognitive function, and social and behavioral deficits. In a retrospective study of 101 children with brain tumors treated with cranial radiation, 5 percent developed radiation necrosis [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Depending on the location of the tumor and field of radiation, other complications, such as hearing impairment, hypothalamic and pituitary endocrinopathies, and visual impairment secondary to cataracts, optic neuropathy, retinopathy, or cortical blindness, may arise.</p><p></p><p>Various strategies, such as decreasing the radiation dose for patients with relatively lower-risk disease and three-dimensional conformal radiation therapy, have been adopted to minimize the long-term complications associated with radiation therapy. The latter minimizes radiation to adjacent normal tissue by customizing the treatment to deliver maximum radiation within the contour of the tumor volume, regardless of its shape. Proton beam therapy also minimizes the harmful effects of radiation to neighboring normal tissues because of its unique ability of depositing most of its energy (proton) at the targeted area with minimal exit dose. (See  <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery"</a> and  <a class="medical medical_review" href="/z/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer"</a>.)</p><p>Proton radiation therapy has emerged as a treatment of choice in some brain tumors. Compared with standard photon-based radiation therapy, proton therapy decreases low-dose radiation exposure to uninvolved brain and to structures anterior to the craniospinal axis. In the short term, these features of proton therapy may increase tolerance of concurrent and adjuvant chemotherapy by decreasing hematologic and gastrointestinal side effects [<a href="#rid15">15</a>]. In the long term, proton therapy may reduce the risk of neurocognitive, endocrine, vascular, and developmental sequelae of radiation therapy, as well as the risk of radiation-induced second malignancies [<a href="#rid15">15</a>]. This is particularly important for young children who require radiation therapy as part of their treatment plan. (See  <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Proton beam'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">CHEMOTHERAPY</span><span class="headingEndMark"> — </span>The role of chemotherapy in the treatment of CNS tumors is dependent on the type of tumor and the patient's age.</p><p>Chemotherapy is routinely used in the following clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Older children with embryonal tumors (eg, medulloblastomas, ependymomas, high-grade astrocytomas) in combination with surgery and radiation therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Young children and infants with embryonal tumors, low-grade gliomas, and optic glioma after surgical resection. The goal of chemotherapy in this setting is to delay or replace radiation therapy. This reduces or eliminates the long-term effects of radiation (ie, neurocognitive impairment, developmental delay, and endocrine abnormalities) in this vulnerable population.</p><p></p><p>See the relevant reviews on specific histologic types of tumors for more detailed information on chemotherapy. (See <a class="local">'Introduction'</a> above.)</p><p>The use of chemotherapy for CNS tumors poses a challenge to oncologists. The presence of the blood-brain barrier limits the penetration of most systemically administered chemotherapeutic agents. The following approaches are used to administer these agents and are discussed in greater detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>High-dose or combination systemic therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Intrathecal chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Intratumoral chemotherapy with direct administration of the chemotherapy into the tumor bed</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic administration with disruption of the blood-brain barrier by infusions of hypertonic arabinose or <a class="drug drug_pediatric" data-topicid="12570" href="/z/d/drug information/12570.html" rel="external">mannitol</a></p><p></p><p>An increased understanding of the molecular pathways involved in signal transduction, angiogenesis, and cell growth has led to the development of targeted agents in the treatment of malignant gliomas and other tumors. For example, drugs have been developed that disrupt the vascular endothelial growth factor (VEGF) pathway, which is involved in the formation of the abnormal vasculature observed in malignant gliomas and other tumors. These agents include monoclonal antibodies that bind VEGF, inhibitors of tyrosine kinases within the VEGF pathway, and inhibitors of protein kinase C, a major component of the VEGF pathway. Other new drugs target additional molecular pathways involved in tumor pathogenesis, such as the epidermal growth factor, platelet derived growth factor, integrin, sonic hedgehog, and histone deacetylase systems/pathways.</p><p>Biologic agents, such as interferons (IFN alpha and beta) and gene therapy, have also shown promise in the treatment of malignant gliomas and other CNS tumors.</p><p class="headingAnchor" id="H102315727"><span class="h1">PALLIATIVE CARE</span><span class="headingEndMark"> — </span>Certain brain tumors (eg, high-grade gliomas) have a poor prognosis, with five-year survival rates &lt;20 percent (see <a class="local">'Prognosis'</a> below). In such cases, early involvement of a palliative care team at the time of diagnosis can help support family and caregivers and assist in establishing realistic treatment goals for the patient. Children with brain tumors at the end of life have progressive neurologic deterioration, including loss of the ability to communicate [<a href="#rid16">16</a>]. End-of-life care for these patients needs to provide early anticipatory guidance for families and comfort measures that address the distinct issues in the care of a dying child with a brain tumor. (See  <a class="medical medical_review" href="/z/d/html/6252.html" rel="external">"Pediatric palliative care"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H12"><span class="h2">Survival</span><span class="headingEndMark"> — </span>Survival after diagnosis with a primary brain or other CNS tumor varies considerably, depending on the age of the child and the type of tumor. Based on data from the Central Brain Tumor Registry of the United States (2011 to 2015), pilocytic astrocytoma was the tumor type with the highest survival rates after diagnosis (five-year survival rate of 97 percent), whereas atypical teratoid/rhabdoid tumors, diffuse intrinsic pontine glioma (DIPG), and high-grade gliomas had the lowest survival rates after diagnosis [<a href="#rid17">17,18</a>]. Five-year survival for glioblastoma is only 18 percent [<a href="#rid17">17,18</a>], while two-year survival for DIPG is only around 2 percent. In the United States, CNS tumors account for one-fourth of all cancer deaths in children [<a href="#rid19">19</a>].</p><p>Survival has improved, in part due to advances in diagnostic techniques and histologic classification of tumors, improvement in neurosurgical and radiation oncology techniques, and the utilization of new single and combination chemotherapeutic agents. Despite advances in the care of children with CNS tumors, mortality and morbidity associated with these disorders persist. Improvement in survival and durable remissions has been slower in patients with CNS tumors compared with other cancers, particularly leukemias and lymphomas.</p><p>Late mortality occurs in 15 to 25 percent of patients who survive beyond five years [<a href="#rid20">20,21</a>]. Late mortality is most commonly due to tumor recurrence or progression [<a href="#rid20">20,21</a>]. Other causes of death include secondary malignant tumor and secondary medical conditions [<a href="#rid20">20</a>]. (See <a class="local">'Secondary neoplasms'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Long-term morbidity</span><span class="headingEndMark"> — </span>Pediatric survivors with CNS tumors often have neurologic, cognitive, psychological, and endocrine complications that are due to damage from the tumor itself, its treatment (surgery, radiation, and/or chemotherapy), or subsequent secondary malignancy. The risk of these complications is increased in patients who are younger at the time of diagnosis and treatment (less than three years of age), have hydrocephalus, and/or are treated with cranial radiation [<a href="#rid22">22-24</a>]. (See  <a class="medical medical_review" href="/z/d/html/88801.html" rel="external">"Treatment and prognosis of medulloblastoma", section on 'Neurocognitive impairment'</a>.)</p><p>In the Childhood Cancer Survivor Study, 82 percent of the 2821 five-year survivors of childhood brain tumors reported having at least one chronic medical condition [<a href="#rid21">21</a>]. Compared with their siblings, survivors had an increased risk of developing a new endocrine condition (hazard ratio [HR] 19.8, 95% CI 14.5-27.1), sensory deficit (eg, hearing loss; HR 12.5, 95% CI 8.9-17.6), and neurologic problem (HR 5.6, 95% CI 4.8-6.7). Cranial radiation therapy was associated with an increased risk of subsequent malignancy and neurocognitive impairment.</p><p class="headingAnchor" id="H366937391"><span class="h3">Secondary neoplasms</span><span class="headingEndMark"> — </span>Patients treated for CNS tumors in childhood are at risk of developing secondary neoplasms decades beyond the primary cancer treatment [<a href="#rid21">21,25,26</a>]. Based upon long-term follow-up studies of survivors of childhood CNS tumors, the cumulative incidence of secondary neoplasms 20 years after diagnosis is approximately 10 percent [<a href="#rid21">21,25</a>]. The most common subsequent neoplasms include basal cell carcinoma, meningioma, malignant CNS tumors (eg, glioma and astrocytoma), soft tissue sarcomas, and thyroid cancers. The risk of developing a secondary CNS neoplasm is associated with the maximum cranial radiation dose given [<a href="#rid21">21,27</a>]. The risk does not appear to be higher after exposure to multimodal therapy compared with radiation alone for medulloblastoma [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Secondary tumor formation'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Neurocognitive effects</span><span class="headingEndMark"> — </span>Neurocognitive impairment is a common complication in children with CNS tumors [<a href="#rid28">28-30</a>]. Younger age at diagnosis and treatment is the most consistently identified risk factor; others include cranial radiotherapy, neurosurgical resection, perioperative complications, and ototoxicity [<a href="#rid31">31</a>].</p><p>Scholastic impairment was illustrated in a study from the Finnish Cancer Registry that compared school performance at age 16 years of patients with CNS tumors with age-matched controls [<a href="#rid28">28</a>]. Although 94 percent of patients were able to finish their education at the usual age, patients had lower grades in all school subjects compared with controls, with the greatest difference in foreign language. In particular, brain tumor survivors who were diagnosed as preschoolers had 18-fold higher odds (95% CI 15.0-23.5) of a special education history than did those in the sibling group.</p><p>In a report from the Children's Oncology Group of 93 patients with a low-grade brain tumor who were treated only with surgical excision, patients were more likely to have below-average scores compared with published normative scores in intelligence quotient (IQ), academic performance, visual and motor skills, and adaptive behavior (55 percent compared with the expected normative rate of 25 percent) [<a href="#rid29">29</a>].</p><p>Late neurocognitive complications of cranial irradiation are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Neurocognitive effects'</a>.)</p><p class="headingAnchor" id="H6839033"><span class="h3">Cerebrovascular disease</span><span class="headingEndMark"> — </span>Survivors of childhood CNS tumors treated with radiation therapy are at increased risk for late-occurring cerebrovascular complications including stroke [<a href="#rid32">32-34</a>]. Late cerebrovascular complications of cranial irradiation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Cerebrovascular effects'</a>.)</p><p class="headingAnchor" id="H1791084637"><span class="h3">Endocrine abnormalities</span><span class="headingEndMark"> — </span>The hypothalamic-pituitary-adrenal (HPA) axis may be injured by cranial irradiation, which may lead to endocrine abnormalities, including thyroid disease, growth delay, obesity, abnormal puberty, and infertility [<a href="#rid35">35,36</a>]. In a report from the Childhood Cancer Survivor Study group, adult survivors of childhood brain tumors compared with their siblings are at increased risk for endocrine abnormalities, including growth hormone deficiency (relative risk [RR] 278, 95% CI 111-694), the need for medications to induce puberty (RR 86, 95% CI 31-238), and hypothyroidism (RR 14.3, 95% CI 9.7-21.0) [<a href="#rid22">22</a>].</p><p>Weight gain and obesity affect approximately one-third of survivors [<a href="#rid36">36</a>]. Contributing factors include HPA axis dysfunction as well as impaired mobility, visual impairment, disrupted sleep, medication side effects, and reduced physical activity [<a href="#rid37">37,38</a>]. In one large cohort of brain tumor survivors between 4 and 20 years of age (median 15 years), 29 percent were overweight or obese, a rate approximately twice as high as expected for the general population [<a href="#rid36">36</a>].</p><p>In female survivors, radiation therapy and diagnosis before four years of age are associated with an increased risk for menarche abnormalities, including both late and early menarche [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">"Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood"</a> and  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Endocrinopathies'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Psychological effects</span><span class="headingEndMark"> — </span>In a study from the Childhood Cancer Survivor Study group, adult survivors of childhood brain cancer compared with their siblings had an increased rate of symptoms of physiologic distress, particularly depression [<a href="#rid40">40</a>]. Multivariate analyses of risk factors demonstrated no association of distress with any treatment-related variable.</p><p class="headingAnchor" id="H16"><span class="h3">Social effects</span><span class="headingEndMark"> — </span>Compared with age- and sex-matched controls or siblings, adult survivors of brain tumors are less likely to be married and are at risk for lower rates of employment, lower education and income levels, and high health care costs [<a href="#rid41">41,42</a>]. Some of these associations may be mediated by deficits in social cognition and executive function [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3305871187"><span class="h1">SURVIVORSHIP</span><span class="headingEndMark"> — </span>Specific long-term follow-up guidelines for survivors of childhood CNS tumors have been published by the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=6253" target="_blank">Children's Oncology Group</a> [<a href="#rid44">44</a>].</p><p>Additional topics related to cancer survivorship in children and adolescents include: </p><p class="bulletIndent1"><span class="glyph">●</span>Psychosocial needs (see  <a class="medical medical_review" href="/z/d/html/17015.html" rel="external">"Overview of cancer survivorship in adolescents and young adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fertility and parenthood (see  <a class="medical medical_review" href="/z/d/html/4801.html" rel="external">"Overview of infertility and pregnancy outcome in cancer survivors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for subsequent cancers (see  <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Screening for subsequent primary cancers'</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery and diagnostic confirmation</strong> – An open surgical procedure is the preferred approach for most childhood brain tumors to obtain tissue for a histologic diagnosis and bulk removal where possible. Stereotactic biopsy is used for tumors deeply located in the brain, which are not amenable to open surgical intervention because of the high risk of irreversible neurologic impairment. Intraventricular and periventricular lesions can be biopsied endoscopically. (See <a class="local">'Management strategy'</a> above and <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of complications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased intracranial pressure</strong> – Patients with clinical and/or neuroimaging evidence of elevated intracranial pressure (ICP) require urgent neurosurgical intervention (eg, tumor resection and/or placement of a shunt to relieve hydrocephalus). In addition, for most children undergoing surgery for tumor resection, we suggest perioperative glucocorticoid therapy to reduce peritumoral edema (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A typical regimen consists of <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> 0.25 to 0.5 mg/kg given orally or intravenously every six hours (maximum dose 16 mg per day). (See <a class="local">'Elevated intracranial pressure'</a> above and  <a class="medical medical_review" href="/z/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors", section on 'Initiation of glucocorticoids'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizures</strong> – Patients with brain tumors commonly experience seizures, which may require antiseizure medication. The choice of agent is based on drug interactions, safety profile, and clinician and patient preference. (See  <a class="medical medical_review" href="/z/d/html/5181.html" rel="external">"Seizures in patients with primary and metastatic brain tumors"</a>.)</p><p></p><p class="bulletIndent2">We suggest<strong> not</strong> using prophylactic anticonvulsants in patients without a history of seizures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, some neurosurgeons may reasonably choose to provide seizure prophylaxis in the perioperative setting if the patient is deemed to be at high risk of postoperative seizures based on the location of the tumor and/or extent of resection. (See <a class="local">'Seizures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endocrine dysfunction – </strong>Children with certain brain tumors (eg, lesions located in the hypothalamus or pituitary gland) may present with endocrine abnormalities, including growth failure, hypothyroidism, and arginine vasopressin deficiency (AVP-D). Management focuses on treating the specific endocrine abnormalities and may require hormonal replacement therapy. (See <a class="local">'Endocrine abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radiation therapy</strong> – The use of radiation therapy is dependent on the histologic diagnosis of the tumor. Although radiation therapy is an effective adjunct, it is associated with both acute and long-term complications. The timing, dose, and field of radiation are based on the histology, tumor location and size, stage of the tumor, expected patterns of spread, and availability of effective chemotherapy agents. (See <a class="local">'Radiation therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemotherapy</strong> – The use of chemotherapy is dependent on the underlying tissue histology. It is routinely used in combination with surgery and radiation therapy for older children to treat embryonal tumors (eg, medulloblastoma). In young children and infants with embryonal tumors, low-grade gliomas, and optic glioma, chemotherapy is used after surgical resection to delay or avoid the need for radiation therapy. (See <a class="local">'Chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Survival after diagnosis with a primary brain or other CNS tumor varies considerably, depending on the age of the child and the type of tumor. Survivors of pediatric CNS tumors are at risk for secondary neoplasms and neurologic, cognitive, endocrine, social, and psychological sequelae. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1">For children with life-threatening tumors, pediatric palliative care is an important component of management. (See  <a class="medical medical_review" href="/z/d/html/6252.html" rel="external">"Pediatric palliative care"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008; 112:416.</a></li><li><a class="nounderline abstract_t">Ostrom QT, de Blank PM, Kruchko C, et al. Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol 2015; 16 Suppl 10:x1.</a></li><li><a class="nounderline abstract_t">Albright AL, Sposto R, Holmes E, et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 2000; 47:879.</a></li><li class="breakAll">Blaney SM, Hass-Kogan D, Poussaint TY, et al. Gliomas, ependymomas, and other nonembryonal tumors of the central nervous system. In: Principles and practice of pediatric oncology, 6th ed, Pizzo P, Poplack D (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.717.</li><li><a class="nounderline abstract_t">Hall WA, Truwit CL. 1.5 T: spectroscopy-supported brain biopsy. Neurosurg Clin N Am 2005; 16:165.</a></li><li><a class="nounderline abstract_t">Ahn ES, Goumnerova L. Endoscopic biopsy of brain tumors in children: diagnostic success and utility in guiding treatment strategies. J Neurosurg Pediatr 2010; 5:255.</a></li><li><a class="nounderline abstract_t">Matthews PM, Wylezinska M, Cadoux-Hudson T. Novel approaches to imaging brain tumors. Hematol Oncol Clin North Am 2001; 15:609.</a></li><li><a class="nounderline abstract_t">Yamaguchi F, Takahashi H, Teramoto A. Intra-operative detection of motor pathways using a simple electrode provides safe brain tumor surgery. J Clin Neurosci 2007; 14:1106.</a></li><li><a class="nounderline abstract_t">Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:103.</a></li><li><a class="nounderline abstract_t">van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6:421.</a></li><li><a class="nounderline abstract_t">Hardesty DA, Sanborn MR, Parker WE, Storm PB. Perioperative seizure incidence and risk factors in 223 pediatric brain tumor patients without prior seizures. J Neurosurg Pediatr 2011; 7:609.</a></li><li><a class="nounderline abstract_t">Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:1886.</a></li><li><a class="nounderline abstract_t">Sayegh ET, Fakurnejad S, Oh T, et al. Anticonvulsant prophylaxis for brain tumor surgery: determining the current best available evidence. J Neurosurg 2014; 121:1139.</a></li><li><a class="nounderline abstract_t">Plimpton SR, Stence N, Hemenway M, et al. Cerebral radiation necrosis in pediatric patients. Pediatr Hematol Oncol 2015; 32:78.</a></li><li><a class="nounderline abstract_t">McGovern SL, Okcu MF, Munsell MF, et al. Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys 2014; 90:1143.</a></li><li><a class="nounderline abstract_t">Zelcer S, Cataudella D, Cairney AE, Bannister SL. Palliative care of children with brain tumors: a parental perspective. Arch Pediatr Adolesc Med 2010; 164:225.</a></li><li><a class="nounderline abstract_t">Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014; 16 Suppl 4:iv1.</a></li><li><a class="nounderline abstract_t">Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20:iv1.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Trends in childhood cancer mortality--United States, 1990-2004. MMWR Morb Mortal Wkly Rep 2007; 56:1257.</a></li><li><a class="nounderline abstract_t">Morris EB, Gajjar A, Okuma JO, et al. Survival and late mortality in long-term survivors of pediatric CNS tumors. J Clin Oncol 2007; 25:1532.</a></li><li><a class="nounderline abstract_t">Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101:946.</a></li><li><a class="nounderline abstract_t">Gerber NU, Zehnder D, Zuzak TJ, et al. Outcome in children with brain tumours diagnosed in the first year of life: long-term complications and quality of life. Arch Dis Child 2008; 93:582.</a></li><li><a class="nounderline abstract_t">Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5:399.</a></li><li><a class="nounderline abstract_t">Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005; 23:7152.</a></li><li><a class="nounderline abstract_t">Tsui K, Gajjar A, Li C, et al. Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. Neuro Oncol 2015; 17:448.</a></li><li><a class="nounderline abstract_t">Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102:1083.</a></li><li><a class="nounderline abstract_t">Bowers DC, Verbruggen LC, Kremer LCM, et al. Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2021; 22:e196.</a></li><li><a class="nounderline abstract_t">Lähteenmäki PM, Harila-Saari A, Pukkala EI, et al. Scholastic achievements of children with brain tumors at the end of comprehensive education: a nationwide, register-based study. Neurology 2007; 69:296.</a></li><li><a class="nounderline abstract_t">Ris MD, Beebe DW, Armstrong FD, et al. Cognitive and adaptive outcome in extracerebellar low-grade brain tumors in children: a report from the Children's Oncology Group. J Clin Oncol 2008; 26:4765.</a></li><li><a class="nounderline abstract_t">de Ruiter MA, van Mourik R, Schouten-van Meeteren AY, et al. Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis. Dev Med Child Neurol 2013; 55:408.</a></li><li><a class="nounderline abstract_t">Oyefiade A, Paltin I, De Luca CR, et al. Cognitive Risk in Survivors of Pediatric Brain Tumors. J Clin Oncol 2021; 39:1718.</a></li><li><a class="nounderline abstract_t">Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006; 24:5277.</a></li><li><a class="nounderline abstract_t">Partap S. Stroke and cerebrovascular complications in childhood cancer survivors. Semin Pediatr Neurol 2012; 19:18.</a></li><li><a class="nounderline abstract_t">Passos J, Nzwalo H, Marques J, et al. Late Cerebrovascular Complications After Radiotherapy for Childhood Primary Central Nervous System Tumors. Pediatr Neurol 2015; 53:211.</a></li><li><a class="nounderline abstract_t">Vern-Gross TZ, Bradley JA, Rotondo RL, Indelicato DJ. Fertility in childhood cancer survivors following cranial irradiation for primary central nervous system and skull base tumors. Radiother Oncol 2015; 117:195.</a></li><li><a class="nounderline abstract_t">van Schaik J, van Roessel IMAA, Schouten-van Meeteren NAYN, et al. High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction. J Clin Oncol 2021; 39:1264.</a></li><li><a class="nounderline abstract_t">Green DM, Cox CL, Zhu L, et al. Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2012; 30:246.</a></li><li><a class="nounderline abstract_t">Smith WA, Li C, Nottage KA, et al. Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer 2014; 120:2742.</a></li><li><a class="nounderline abstract_t">Armstrong GT, Whitton JA, Gajjar A, et al. Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer 2009; 115:2562.</a></li><li><a class="nounderline abstract_t">Zebrack BJ, Gurney JG, Oeffinger K, et al. Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. J Clin Oncol 2004; 22:999.</a></li><li><a class="nounderline abstract_t">Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27:2390.</a></li><li><a class="nounderline abstract_t">Pickering L, Main KM, Feldt-Rasmussen U, et al. Survival and long-term socioeconomic consequences of childhood and adolescent onset of brain tumours. Dev Med Child Neurol 2023; 65:942.</a></li><li><a class="nounderline abstract_t">Papini C, Willard VW, Gajjar A, et al. Social cognition and adjustment in adult survivors of pediatric central nervous system tumors. Cancer 2023; 129:3064.</a></li><li><a class="nounderline abstract_t">Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.</a></li></ol></div><div id="topicVersionRevision">Topic 6253 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18074355" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Trends in childhood cancer incidence in the U.S. (1992-2004).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25542864" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11014428" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11014428" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561536" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 1.5 T: spectroscopy-supported brain biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20192642" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Endoscopic biopsy of brain tumors in children: diagnostic success and utility in guiding treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11676276" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Novel approaches to imaging brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17884505" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intra-operative detection of motor pathways using a simple electrode provides safe brain tumor surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19957014" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434097" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21631197" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Perioperative seizure incidence and risk factors in 223 pediatric brain tumor patients without prior seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10822423" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170671" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Anticonvulsant prophylaxis for brain tumor surgery: determining the current best available evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23647507" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cerebral radiation necrosis in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25311260" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194254" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Palliative care of children with brain tumors: a parental perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25304271" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30445539" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18059256" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Trends in childhood cancer mortality--United States, 1990-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442996" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Survival and late mortality in long-term survivors of pediatric CNS tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19535780" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634182" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Outcome in children with brain tumours diagnosed in the first year of life: long-term complications and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15231246" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Late neurocognitive sequelae in survivors of brain tumours in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192599" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25395462" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634481" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33845037" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636068" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Scholastic achievements of children with brain tumors at the end of comprehensive education: a nationwide, register-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779602" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cognitive and adaptive outcome in extracerebellar low-grade brain tumors in children: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157447" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33886348" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cognitive Risk in Survivors of Pediatric Brain Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088567" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22641072" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Stroke and cerebrovascular complications in childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26302700" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Late Cerebrovascular Complications After Radiotherapy for Childhood Primary Central Nervous System Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26475251" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fertility in childhood cancer survivors following cranial irradiation for primary central nervous system and skull base tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33621126" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184380" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070001" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19309737" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15020603" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224833" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Social outcomes in the Childhood Cancer Survivor Study cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36451275" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Survival and long-term socioeconomic consequences of childhood and adolescent onset of brain tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37329245" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Social cognition and adjustment in adult survivors of pediatric central nervous system tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15576413" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
